| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.068 | 0.04 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.09 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.059 | 0.04 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |